Mar. 19 at 6:02 PM
$NAGE - Comparative efficacy of a standardized herbal composition LN22199, nicotinamide riboside, and their combination on NAD+ metabolism in healthy aging adults
This was published late 2025 so we may have seen it before, but seems timely as the company behind this, Blue Helix, is at the upcomming NAD conference in Copenhagen as well as Prof. Mathias Ziegler, University Bergin Norway who reportedly co-developed it. Might make for an interesting sideline meeting-- they are looking for partners.
The best results came from using a combination of LN22199, which raises NAD while supressing CD38. Supressing CD38 isn't a new idea, and I don't know if it is actually a good idea, but haven't seen it in a product like this.
"Outcomes included NAD+ levels, CD38 activity, inflammatory biomarkers, cognitive function, physical performance, and quality-of-life measures."
https://www.sciencedirect.com/science/article/pii/S1756464625004578?via%3Dihub
